EUVIMEDEUVIMED entdecken
Crossref

Impact of screening programme to prevent anal cancer in high‐risk patients with HIV

Eloïse Leclerc, Christine Jacomet iD, Laurent Siproudhis, Laurent Abramowitz, Bruno Pereira, Anthony Buisson iD

HIV Medicine · 2024

DOI: 10.1111/hiv.13594 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2024. Verfasst von Eloïse Leclerc und 5 weiteren Autor:innen. Beteiligte Einrichtung: Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: HIV Infections, Sexual and Gender Minorities, Anus Neoplasms, Papillomavirus Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We assessed the impact of a nationwide screening programme to reduce the risk of anal cancer in a large cohort of high‐risk patients with HIV.

Methods

From a large database from one referral centre, all high‐risk patients with HIV (men who have sex with men, history of anal or genital warts, or previous cervix human papillomavirus‐related lesions) who were eligible to enter the French anal cancer screening programme (2011–2020) were retrospectively included. Adherence to the screening programme was defined as no interval >18 months between two visits. Standardized management included perianal visualization and standard anoscopy with biopsies of macroscopic abnormalities.

Results

Overall, 700 patients with HIV were included (median follow‐up 8.4 years [interquartile range 4.3–9.2] and 1491.6 patient‐years), and 336 had one or more proctology visit. A total of 13 patients were diagnosed with anal squamous cell carcinomas. The risk of anal cancer was higher with anal intra‐epithelial neoplasia grade 3 (AIN3; hazard ratio [HR] 44.5 [95% confidence interval {CI} 11.2–176.6], p < 0.001), AIN2 (HR 11.9 [95% CI 2.1–66.9], p = 0.005), or high‐grade dysplasia (HR 23.4 [95% CI 7.9–69.1], p < 0.001) than with low‐grade dysplasia or no lesion. Among the patients who were strictly adherent to the screening programme (4.6% [32/700]), we did not report any AIN or anal cancer, but we also did not observe any significant reduction in the risk of anal cancer ( p = 0.51), AIN3 ( p = 0.28), high‐grade dysplasia ( p = 0.19), or any AIN lesions ( p = 0.10) compared with non‐adherent patients. In contrast, screened patients were more likely to be diagnosed with anal warts (HR 3.71 [95% CI 2.14–6.42], p < 0.001).

Conclusion

Macroscopic high‐grade dysplasia lesions are associated with a higher risk of developing anal cancer. Despite finding no cases of cancer during the screening programme, we also did not demonstrate a clear benefit from our screening programme for the prevention of anal cancer in high‐risk patients with HIV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsSexual and Gender MinoritiesAnus NeoplasmsPapillomavirus InfectionsMaleFemaleHumansHomosexuality, MaleRetrospective StudiesEarly Detection of CancerPapillomaviridae

Stichwörter der Autor:innen

anal canceranal dysplasiaanal intra‐epithelial neoplasiahuman immunodeficiency virusscreening programme

Autor:innen und Institutionen

  • Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France.
  • Université Clermont Auvergne, CHU Clermont-Ferrand, Service de Maladies infectieuses et tropicales, Clermont-Ferrand, France.
  • CHU Rennes, Univ Rennes, INSERM, CIC1414, Institut NUMECAN (Nutrition Metabolisms and Cancer), Rennes, France.
  • Gastro-entérologie et proctologie, hôpital Bichat, AP-HP, Paris, France.
  • Université Clermont Auvergne, CHU Clermont-Ferrand, DRCI, Unité de Biostatistiques, Clermont-Ferrand, France.
  • Université Clermont Auvergne, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France.

ORCID-Profile: Christine Jacomet, Anthony Buisson

Zitieren

APA

Leclerc, E., Jacomet, C., Siproudhis, L., Abramowitz, L., Pereira, B., & Buisson, A. (2024). Impact of screening programme to prevent anal cancer in high‐risk patients with HIV. HIV Medicine. https://doi.org/10.1111/hiv.13594

Vancouver

Leclerc E, Jacomet C, Siproudhis L, Abramowitz L, Pereira B, Buisson A. Impact of screening programme to prevent anal cancer in high‐risk patients with HIV. HIV Medicine. 2024. doi:10.1111/hiv.13594

BibTeX
@article{Leclerc2024,
  author = {Leclerc, Eloïse and Jacomet, Christine and Siproudhis, Laurent and Abramowitz, Laurent and Pereira, Bruno and Buisson, Anthony},
  title = {Impact of screening programme to prevent anal cancer in high‐risk patients with HIV},
  journal = {HIV Medicine},
  year = {2024},
  doi = {10.1111/hiv.13594}
}
Kostenlos starten →